File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Etoposide combination chemotherapy in refractory ovarian malignant germ cell tumor

TitleEtoposide combination chemotherapy in refractory ovarian malignant germ cell tumor
Authors
Issue Date1990
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 1990, v. 39 n. 2, p. 123-126 How to Cite?
AbstractThirty-three patients with malignant germ cell tumor of the ovary received postoperative vincristine, dactinomycin, and cyclosphosphamide (VAC) treatment. Eight failed VAC treatment and received etoposide, bleomycin, and cisplatin (PEB) combination chemotherapy. Three were cured and remained disease free 24-79 months after completion of PEB therapy.
Persistent Identifierhttp://hdl.handle.net/10722/147856
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, LCen_HK
dc.contributor.authorCollins, RJen_HK
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorMa, HKen_HK
dc.date.accessioned2012-05-29T06:09:35Z-
dc.date.available2012-05-29T06:09:35Z-
dc.date.issued1990en_HK
dc.identifier.citationGynecologic Oncology, 1990, v. 39 n. 2, p. 123-126en_HK
dc.identifier.issn0090-8258en_HK
dc.identifier.urihttp://hdl.handle.net/10722/147856-
dc.description.abstractThirty-three patients with malignant germ cell tumor of the ovary received postoperative vincristine, dactinomycin, and cyclosphosphamide (VAC) treatment. Eight failed VAC treatment and received etoposide, bleomycin, and cisplatin (PEB) combination chemotherapy. Three were cured and remained disease free 24-79 months after completion of PEB therapy.en_HK
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_HK
dc.relation.ispartofGynecologic Oncologyen_HK
dc.subject.meshCarboplatin - Pharmacologyen_US
dc.subject.meshCell Division - Drug Effectsen_US
dc.subject.meshCell Lineen_US
dc.subject.meshCell Survival - Drug Effectsen_US
dc.subject.meshCisplatin - Pharmacologyen_US
dc.subject.meshDrug Screening Assays, Antitumoren_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshOvarian Neoplasmsen_US
dc.titleEtoposide combination chemotherapy in refractory ovarian malignant germ cell tumoren_HK
dc.typeArticleen_HK
dc.identifier.emailCollins, RJ:rcollins@hkucc.hku.hken_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityCollins, RJ=rp00251en_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0090-8258(90)90417-Jen_HK
dc.identifier.pmid2227584-
dc.identifier.scopuseid_2-s2.0-0025119677en_HK
dc.identifier.volume39en_HK
dc.identifier.issue2en_HK
dc.identifier.spage123en_HK
dc.identifier.epage126en_HK
dc.identifier.isiWOS:A1990EH62200005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK
dc.identifier.scopusauthoridCollins, RJ=7403350455en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridMa, HK=7403095603en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats